VRTX•benzinga•
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Summary
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 31, 2025 by benzinga